lapatinib has been researched along with Bone Cancer in 11 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (27.27) | 29.6817 |
| 2010's | 8 (72.73) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bozzi, F; Casale, A; Casali, PG; Conca, E; Crippa, F; Gronchi, A; Lo Vullo, S; Mariani, L; Marrari, A; Messina, A; Morosi, C; Negri, T; Palassini, E; Palmerini, E; Pilotti, S; Stacchiotti, S; Tamborini, E | 1 |
| Bian, L; Jiang, Z; Wang, T; Zhang, S | 1 |
| Gao, S; Liu, ZL; Long, XH; Luo, QF; Peng, AF; Wen, HC; Zhang, GM; Zhang, L; Zhou, RP; Zhou, Y | 1 |
| Bozzi, F; Conca, E; Dagrada, G; Gronchi, A; Manenti, G; Messina, A; Panizza, P; Pierotti, MA; Pilotti, S; Stacchiotti, S; Tamborini, E | 1 |
| Bregni, G; de Braud, F; Di Cosimo, S; Galli, G; Gevorgyan, A; Porcu, L; Serpico, D; Tessari, A; Torri, V | 1 |
| Agerbaek, M; Cerbone, L; Collette, S; Daugaard, G; Marreaud, S; Sengeløv, L; Sternberg, CN; Van Herpen, C; Zhang, J | 1 |
| Ajgal, Z; Alexandre, J; Arrondeau, J; Goldwasser, F; Huillard, O; Hulin, A; Lavaud, P; Rousseau, B | 1 |
| Adamo, B; Cheang, MC; Ellis, C; Gagnon, R; Galván, P; Johnston, S; Muñoz, M; Nuciforo, P; Paré, L; Prat, A; Press, MF; Viladot, M | 1 |
| Benowitz, S | 1 |
| Heinemann, V; Rack, B; Salat, C; Schindlbeck, C; Sommer, H; Walther, J | 1 |
1 review(s) available for lapatinib and Bone Cancer
| Article | Year |
|---|---|
[Metastatic breast cancer--new methods of treatment].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Clinical Trials, Phase III as Topic; Diphosphonates; Female; Histocytochemistry; Humans; Lapatinib; Neoplasm Metastasis; Osteonecrosis; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Risk Factors; Signal Transduction; Time Factors; Trastuzumab | 2008 |
3 trial(s) available for lapatinib and Bone Cancer
| Article | Year |
|---|---|
Phase II study on lapatinib in advanced EGFR-positive chordoma.
Topics: Adult; Aged; Antineoplastic Agents; Bone Neoplasms; Chordoma; Disease-Free Survival; Drug Administration Schedule; ErbB Receptors; Female; Humans; Lapatinib; Male; Middle Aged; Quinazolines; Sacrum; Skull Base; Treatment Outcome | 2013 |
Trastuzumab plus capecitabine vs. lapatinib plus capecitabine in patients with trastuzumab resistance and taxane-pretreated metastatic breast cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Capecitabine; Deoxycytidine; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Lapatinib; Liver Neoplasms; Lung Neoplasms; Middle Aged; Prospective Studies; Quinazolines; Taxoids; Trastuzumab; Treatment Outcome | 2013 |
Results from a Phase I Study of Lapatinib with Gemcitabine and Cisplatin in Advanced or Metastatic Bladder Cancer: EORTC Trial 30061.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Bone Neoplasms; Cisplatin; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; ErbB Receptors; Febrile Neutropenia; Female; Gemcitabine; Humans; International Cooperation; Lapatinib; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Maximum Tolerated Dose; Middle Aged; Quinazolines; Receptor, ErbB-2; Renal Insufficiency; Treatment Outcome; Urinary Bladder Neoplasms | 2016 |
7 other study(ies) available for lapatinib and Bone Cancer
| Article | Year |
|---|---|
Lapatinib alters the malignant phenotype of osteosarcoma cells via downregulation of the activity of the HER2-PI3K/AKT-FASN axis in vitro.
Topics: Antineoplastic Agents; Apoptosis; Bone Neoplasms; Cell Line, Tumor; Cell Movement; Cell Proliferation; Fatty Acid Synthase, Type I; Humans; Lapatinib; Neoplasm Invasiveness; Osteosarcoma; Phosphatidylinositol 3-Kinases; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinazolines; Receptor, ErbB-2; Signal Transduction | 2014 |
Development of transplantable human chordoma xenograft for preclinical assessment of novel therapeutic strategies.
Topics: Animals; Antineoplastic Agents; Biomarkers, Tumor; Blotting, Western; Bone Neoplasms; Chordoma; ErbB Receptors; Female; Humans; Immunoenzyme Techniques; In Situ Hybridization, Fluorescence; Lapatinib; Magnetic Resonance Imaging; Mice; Mice, Nude; Neoplasm Recurrence, Local; Quinazolines; Sacrum; Signal Transduction; Transplantation, Heterologous; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2014 |
Disease progression pattern in metastatic breast cancer patients treated with anti-HER2 therapies.
Topics: Adult; Aged; Antineoplastic Agents; Bone Neoplasms; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Central Nervous System Neoplasms; Disease Progression; Female; Humans; Lapatinib; Liver Neoplasms; Lung Neoplasms; Middle Aged; Prognosis; Proportional Hazards Models; Quinazolines; Receptor, ErbB-2; Retrospective Studies; Time Factors; Trastuzumab; Treatment Outcome | 2015 |
Bi-weekly very-high-dose lapatinib: an easy-to-use active option in HER-2-positive breast cancer patients with meningeal carcinomatosis.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Diarrhea; Female; Humans; Lapatinib; Liver Neoplasms; Magnetic Resonance Imaging; Meningeal Carcinomatosis; Quinazolines; Receptor, ErbB-2; Trastuzumab; Treatment Outcome | 2016 |
Prognostic Value of Intrinsic Subtypes in Hormone Receptor-Positive Metastatic Breast Cancer Treated With Letrozole With or Without Lapatinib.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Bone Neoplasms; Breast Neoplasms; Disease-Free Survival; Female; Humans; Kaplan-Meier Estimate; Lapatinib; Letrozole; Middle Aged; Nitriles; Prognosis; Proportional Hazards Models; Quinazolines; Receptor, ErbB-2; Retrospective Studies; Treatment Outcome; Triazoles | 2016 |
As metastasis yields its biological secrets, researchers hope to apply findings.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Biomarkers, Tumor; Bone Neoplasms; Brain Neoplasms; Breast Neoplasms; Denosumab; Drug Design; ErbB Receptors; Female; Humans; Lapatinib; Male; Mice; Neoplasm Metastasis; Prostatic Neoplasms; Quinazolines; RANK Ligand; Receptor, ErbB-2; Trastuzumab | 2008 |
Highlights From ECCO 13-The European Cancer Conference Paris, France October 30 to November 3, 2005.
Topics: Administration, Oral; Anthracyclines; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Carboplatin; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Diphosphonates; Docetaxel; Europe; Female; Humans; Ibandronic Acid; Lapatinib; Quinazolines; Taxoids; Trastuzumab | 2005 |